Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 62 publications
Prognostic Implications of Personalized Circulating Tumor DNA Testing in Patients with Advanced Urothelial Carcinoma Treated with Enfortumab Vedotin ± Pembrolizumab.
Journal: European urology oncology
Published: March 20, 2026
Autophagolysosomal exocytosis inverts Src kinase onto the cell surface in cancer.
Journal: Science (New York, N.Y.)
Published: March 12, 2026
Prognostic Utility of ctDNA for Trimodality Therapy Outcomes in Muscle Invasive Bladder Cancer.
Journal: Clinical genitourinary cancer
Published: December 17, 2025
Synergistic Treatment of Prostate Cancer and Multiple Myeloma using CD46-Targeted Radioimmunotherapy Antibody-Drug Conjugates.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: October 28, 2025
Genome-wide CRISPR screens identify PTGES3 as a novel AR modulator.
Journal: bioRxiv : the preprint server for biology
Published: June 12, 2025
Defining CDK12 as a tumor suppressor and therapeutic target in mouse models of tubo-ovarian high-grade serous carcinoma.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: June 12, 2025
Identification and Characterization of PLUTO-201, a Novel Long Non-Coding RNA Associated with Poor Outcomes in Prostate Cancer.
Journal: bioRxiv : the preprint server for biology
Published: June 06, 2025
Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer.
Journal: Nature genetics
Published: September 16, 2024
Effective Treatment of Disseminated Prostate Cancer Using CD46-Targeted 225Ac Therapy.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: August 30, 2024
Patients Can Administer Mobile Audio Recordings to Increase Knowledge in Advanced Prostate Cancer.
Journal: Cancer medicine
Published: August 16, 2024
Modulating the PPARγ pathway upregulates NECTIN4 and enhances chimeric antigen receptor (CAR) T cell therapy in bladder cancer.
Journal: Nature communications
Published: July 02, 2024
CDK12 loss drives prostate cancer progression, transcription-replication conflicts, and synthetic lethality with paralog CDK13.
Journal: Cell reports. Medicine
Published: May 02, 2024
Last Updated: 09/26/2026